Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1988 1
1991 1
1992 1
1993 2
1994 12
1995 12
1996 5
1997 10
1998 5
1999 3
2000 4
2001 5
2002 5
2003 7
2004 7
2005 13
2006 14
2007 13
2008 10
2009 12
2010 23
2011 36
2012 38
2013 30
2014 29
2015 26
2016 38
2017 30
2018 31
2019 29
2020 29
2021 40
2022 38
2023 34
2024 10

Text availability

Article attribute

Article type

Publication date

Search Results

512 results

Results by year

Filters applied: . Clear all
Page 1
CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance.
Nilsson MB, Yang Y, Heeke S, Patel SA, Poteete A, Udagawa H, Elamin YY, Moran CA, Kashima Y, Arumugam T, Yu X, Ren X, Diao L, Shen L, Wang Q, Zhang M, Robichaux JP, Shi C, Pfeil AN, Tran H, Gibbons DL, Bock J, Wang J, Minna JD, Kobayashi SS, Le X, Heymach JV. Nilsson MB, et al. Among authors: moran ca. Cancer Cell. 2023 Feb 13;41(2):340-355.e6. doi: 10.1016/j.ccell.2023.01.007. Cancer Cell. 2023. PMID: 36787696 Free PMC article.
Effective therapeutic strategies are needed for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations that acquire resistance to EGFR tyrosine kinase inhibitors (TKIs) mediated by epithelial-to-mesenchymal transition (EMT). ...
Effective therapeutic strategies are needed for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EG …
Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.
Ganti AKP, Loo BW, Bassetti M, Blakely C, Chiang A, D'Amico TA, D'Avella C, Dowlati A, Downey RJ, Edelman M, Florsheim C, Gold KA, Goldman JW, Grecula JC, Hann C, Iams W, Iyengar P, Kelly K, Khalil M, Koczywas M, Merritt RE, Mohindra N, Molina J, Moran C, Pokharel S, Puri S, Qin A, Rusthoven C, Sands J, Santana-Davila R, Shafique M, Waqar SN, Gregory KM, Hughes M. Ganti AKP, et al. Among authors: moran c. J Natl Compr Canc Netw. 2021 Dec;19(12):1441-1464. doi: 10.6004/jnccn.2021.0058. J Natl Compr Canc Netw. 2021. PMID: 34902832 Free PMC article.
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Small Cell Lung Cancer (SCLC) provide recommended management for patients with SCLC, including diagnosis, primary treatment, surveillance for relapse, and subsequent treatment. ...
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Small Cell Lung Cancer (SCLC) provide recommended management …
IgA transcytosis and antigen recognition govern ovarian cancer immunity.
Biswas S, Mandal G, Payne KK, Anadon CM, Gatenbee CD, Chaurio RA, Costich TL, Moran C, Harro CM, Rigolizzo KE, Mine JA, Trillo-Tinoco J, Sasamoto N, Terry KL, Marchion D, Buras A, Wenham RM, Yu X, Townsend MK, Tworoger SS, Rodriguez PC, Anderson AR, Conejo-Garcia JR. Biswas S, et al. Among authors: moran c. Nature. 2021 Mar;591(7850):464-470. doi: 10.1038/s41586-020-03144-0. Epub 2021 Feb 3. Nature. 2021. PMID: 33536615 Free PMC article.
Here, using 3 independent cohorts that in total comprise 534 patients with high-grade serous ovarian cancer, we show that robust, protective humoral responses are dominated by the production of polyclonal IgA, which binds to polymeric IgA receptors that are universally exp …
Here, using 3 independent cohorts that in total comprise 534 patients with high-grade serous ovarian cancer, we show that robust, pro …
Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer.
Stewart CA, Gay CM, Xi Y, Sivajothi S, Sivakamasundari V, Fujimoto J, Bolisetty M, Hartsfield PM, Balasubramaniyan V, Chalishazar MD, Moran C, Kalhor N, Stewart J, Tran H, Swisher SG, Roth JA, Zhang J, de Groot J, Glisson B, Oliver TG, Heymach JV, Wistuba I, Robson P, Wang J, Byers LA. Stewart CA, et al. Among authors: moran c. Nat Cancer. 2020 Apr;1:423-436. doi: 10.1038/s43018-019-0020-z. Epub 2020 Feb 17. Nat Cancer. 2020. PMID: 33521652 Free PMC article.
The natural history of small cell lung cancer (SCLC) includes rapid evolution from chemosensitivity to chemoresistance, although mechanisms underlying this evolution remain obscure due to scarcity of post-relapse tissue samples. ...
The natural history of small cell lung cancer (SCLC) includes rapid evolution from chemosensitivity to chemoresistance, although mech …
TGF-β-mediated silencing of genomic organizer SATB1 promotes Tfh cell differentiation and formation of intra-tumoral tertiary lymphoid structures.
Chaurio RA, Anadon CM, Lee Costich T, Payne KK, Biswas S, Harro CM, Moran C, Ortiz AC, Cortina C, Rigolizzo KE, Sprenger KB, Mine JA, Innamarato P, Mandal G, Powers JJ, Martin A, Wang Z, Mehta S, Perez BA, Li R, Robinson J, Kroeger JL, Curiel TJ, Yu X, Rodriguez PC, Conejo-Garcia JR. Chaurio RA, et al. Among authors: moran c. Immunity. 2022 Jan 11;55(1):115-128.e9. doi: 10.1016/j.immuni.2021.12.007. Immunity. 2022. PMID: 35021053 Free PMC article.
Primary Pulmonary Lymphomas.
Piña-Oviedo S, Weissferdt A, Kalhor N, Moran CA. Piña-Oviedo S, et al. Among authors: moran ca. Adv Anat Pathol. 2015 Nov;22(6):355-75. doi: 10.1097/PAP.0000000000000090. Adv Anat Pathol. 2015. PMID: 26452211 Review.
Mediastinal Pathology.
Moran CA. Moran CA. Adv Anat Pathol. 2021 Sep 1;28(5):289-290. doi: 10.1097/PAP.0000000000000313. Adv Anat Pathol. 2021. PMID: 34294658 No abstract available.
Primary mediastinal germ cell tumors.
Sohn A, Moran CA. Sohn A, et al. Among authors: moran ca. Semin Diagn Pathol. 2023 Jan;40(1):37-46. doi: 10.1053/j.semdp.2022.06.010. Epub 2022 Jun 11. Semin Diagn Pathol. 2023. PMID: 35717316 Review.
Stem Cell Theory of Cancer: Origin of Metastasis and Sub-clonality.
Tu SM, Moran C, Norton W, Zacharias NM. Tu SM, et al. Among authors: moran c. Semin Diagn Pathol. 2023 Jan;40(1):63-68. doi: 10.1053/j.semdp.2022.06.012. Epub 2022 Jun 15. Semin Diagn Pathol. 2023. PMID: 35729019 Free article. Review.
We wonder about stochasticity and hierarchy in the genesis and evolution of cancer and of metastasis. We postulate that metastasis may hold the elusive code that makes or breaks a stem-cell versus a genetic theory of cancer. ...We propose that subsequent malignant n …
We wonder about stochasticity and hierarchy in the genesis and evolution of cancer and of metastasis. We postulate that metastasis ma …
Very early onset inflammatory bowel disease.
Moran CJ. Moran CJ. Semin Pediatr Surg. 2017 Dec;26(6):356-359. doi: 10.1053/j.sempedsurg.2017.10.004. Epub 2017 Oct 10. Semin Pediatr Surg. 2017. PMID: 29126503 Review.
Most notably, many of these young children will require long courses of immunosuppression simply as a result of the profoundly early presentation-thus increasing their long-term risks of cancer and opportunistic infections....
Most notably, many of these young children will require long courses of immunosuppression simply as a result of the profoundly early present …
512 results